Works matching DE "LECANEMAB"

Results: 99

AAIC 2025 to Feature Lecanemab Data on Long-Term Efficacy, Real-World Use, and Maintenance Dosing.

Published in:

Patient Care (Online), 2025, p. N.PAG

By:

Jennings, Sydney

Publication type:

Article

Memory Clinic Study Finds Lecanemab's Adverse Events Manageable.

Published in:

JAMA: Journal of the American Medical Association, 2025, v. 334, n. 2, p. 108, doi. 10.1001/jama.2025.7800

By:

Anderer, Samantha

Publication type:

Article

P.006 Cost-effectiveness of Lecanemab for the treatment of early Alzheimer's Disease: a Canadian societal perspective.

Published in:

2025

By:

Burn, O;
Trueman, D;
Molloy, K;
Haynes, AE;
Castellano, K;
Pastor, L;
Wong, E;
Rothwell, S;
Jang, S;
Bodnar, C

Publication type:

Abstract

P.005 Real-world evidence of Lecanemab use in the United Statese.

Published in:

2025

By:

Zhao, C;
Brixner, DI;
Nair, KV;
Toyosaki, H;
Frech, FH;
Rosenbloom, MH

Publication type:

Abstract

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review.

Published in:

BMC Neurology, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12883-025-04302-5

By:

Wang, Yingte;
Yu, Qun;
Chen, Bin;
Zhou, Jing;
Li, Zhiming;
Liao, Wang;
Liu, Jun;
Yang, Airong

Publication type:

Article

Approval: Lecanemab.

Published in:: Brown University Psychopharmacology Update, 2023, v. 34, n. 4, p. 8, doi. 10.1002/pu.31004
Publication type:: Article

Lecanemab slowed cognitive decline in patients with early Alzheimer's disease.

Published in:: Brown University Psychopharmacology Update, 2023, v. 34, n. 4, p. 4, doi. 10.1002/pu.30997
Publication type:: Article

FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose.

Published in:

Patient Care (Online), 2025, p. 1

By:

Jennings, Sydney

Publication type:

Article

Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD.

Published in:

Patient Care (Online), 2025, p. 1

By:

Turner, R. Scott

Publication type:

Article

Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD.

Published in:

Patient Care (Online), 2025, p. 5

By:

Turner, R Scott

Publication type:

Article

FDA Approves Monthly IV Maintenance Dosing of Lecanemab for Adults with Early Alzheimer Dementia: A First in Long-Term Disease Management.

Published in:

Patient Care (Online), 2025, p. 2

By:

Halsey, Grace

Publication type:

Article

Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains.

Published in:

Patient Care (Online), 2025, p. 5

By:

Turner, R. Scott

Publication type:

Article

European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population.

Published in:

Patient Care (Online), 2024, p. 9

By:

Halsey, Grace

Publication type:

Article

New Phase 3 Data Suggest Benefits of Early Lecanemab Initiation on Alzheimer Disease Progression, Support Long-Term Safety.

Published in:

Patient Care (Online), 2024, p. 2

By:

Halsey, Grace

Publication type:

Article

Lecanemab Efficacy Continues at 3 Years of Treatment for Early Alzheimer Disease.

Published in:

Patient Care (Online), 2024, p. 9

By:

Halsey, Grace

Publication type:

Article

UPDATE 6-11-2024: Eisai Files sBLA for Lecanemab-irmb Maintenance Dosing.

Published in:

Patient Care (Online), 2024, p. 3

By:

Halsey, Grace

Publication type:

Article

Eisai Announces Submission of Rolling BLA for SQ Autoinjector-Delivered Lecanemab.

Published in:

Patient Care (Online), 2024, p. 3

By:

Meglio, Marco

Publication type:

Article

Donanemab: Not two without a third.

Published in:

Advances in Clinical & Experimental Medicine, 2023, v. 32, n. 10, p. 1085, doi. 10.17219/acem/172673

By:

Kurkinen, Markku

Publication type:

Article

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.

Published in:

Advances in Clinical & Experimental Medicine, 2023, v. 32, n. 9, p. 943, doi. 10.17219/acem/171379

By:

Kurkinen, Markku

Publication type:

Article

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1593989

By:

Kong, Lingti;
Yang, Xiaohu;
Xu, Jian

Publication type:

Article

Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1599048

By:

Wang, Haoyang;
Pan, Junying;
Zhang, Mingming;
Tan, Zengde

Publication type:

Article

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1561020

By:

Hu, Haoxiang;
Zhao, Yunhan;
Mao, Jiesheng;
He, Jianghai;
Zhang, Yihan;
Ye, Hongyu;
Yang, Xiaokai

Publication type:

Article

Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.

Published in:

Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 614, doi. 10.1002/cpt.2954

By:

Dhruva, Sanket S.;
Kesselheim, Aaron S.;
Woloshin, Steven;
Ji, Robin Z.;
Lu, Zhigang;
Darrow, Jonathan J.;
Redberg, Rita F.

Publication type:

Article

Eisai Presents Real-World Lecanemab Data at AD/PD 2025 Confirming Phase 3 Clinical Trial Findings.

Published in:

Patient Care (Online), 2025, p. N.PAG

By:

Halsey, Grace

Publication type:

Article

Eisai Will Highlight Real-World Experience Data with Lecanemab at 2025 American Academy of Neurology Meeting.

Published in:

2025

By:

Halsey, Grace

Publication type:

Proceeding

Lecanemab: A hope in the management of Alzheimer's disease.

Published in:

Brain Circulation, 2023, v. 9, n. 3, p. 194, doi. 10.4103/bc.bc_10_23

By:

Thakkar, Nandita;
Martis, Preetham Basil;
Kutikuppala, L. V. Simhachalam;
Kuchana, Sai Kiran;
Mohapatra, Ranjan K.

Publication type:

Article

The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.

Published in:

Neurological Sciences, 2024, v. 45, n. 8, p. 3583, doi. 10.1007/s10072-024-07477-w

By:

Abdelazim, Karim;
Allam, Ahmed A.;
Afifi, Badreldin;
Abdulazeem, Hebatullah;
Elbehiry, Ahmed I.

Publication type:

Article

The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment.

Published in:

Cells (2073-4409), 2023, v. 12, n. 23, p. 2669, doi. 10.3390/cells12232669

By:

Cáceres, César;
Heusser, Bernardita;
Garnham, Alexandra;
Moczko, Ewa

Publication type:

Article

Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance.

Published in:

Journal of Applied Pharmaceutical Science, 2025, v. 15, n. 3, p. 30, doi. 10.7324/JAPS.2025.204843

By:

Anil, Aswin A.;
Krishnan, Aishwarya Laxmi;
Chandra, Prashant;
Unnikrishnan, Mazhuvanchery Kesavan

Publication type:

Article

Lecanemab-irmb.

Published in:: American Journal of Health-System Pharmacy, 2023, v. 80, n. 9, p. e81, doi. 10.1093/ajhp/zxad033
Publication type:: Article

Unraveling Alzheimer's: the promise of aducanumab, lecanemab, and donanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2024, v. 60, n. 1, p. 1, doi. 10.1186/s41983-024-00845-5

By:

Ameen, Taha Basit;
Kashif, Syeda Naveera;
Abbas, Syed Muhammad Iraj;
Babar, Kulsoom;
Ali, Syed Muhammad Sinaan;
Raheem, Abdul

Publication type:

Article

Advancing Alzheimer's care: a novel therapy with lecanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2023, v. 59, n. 1, p. 1, doi. 10.1186/s41983-023-00747-y

By:

Teli, Advait;
Dhande, Priti

Publication type:

Article

Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?

Published in:

International Journal of Molecular Sciences, 2024, v. 25, n. 7, p. 3892, doi. 10.3390/ijms25073892

By:

Høilund-Carlsen, Poul F.;
Alavi, Abass;
Castellani, Rudolph J.;
Neve, Rachael L.;
Perry, George;
Revheim, Mona-Elisabeth;
Barrio, Jorge R.

Publication type:

Article

Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.

Published in:

International Journal of Molecular Sciences, 2023, v. 24, n. 18, p. 13900, doi. 10.3390/ijms241813900

By:

Buccellato, Francesca R.;
D'Anca, Marianna;
Tartaglia, Gianluca Martino;
Del Fabbro, Massimo;
Scarpini, Elio;
Galimberti, Daniela

Publication type:

Article

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 6, p. 1553, doi. 10.1007/s00259-023-06177-5

By:

Verger, Antoine;
Yakushev, Igor;
Albert, Nathalie L.;
van Berckel, Bart;
Brendel, Matthias;
Cecchin, Diego;
Fernandez, Pablo Aguiar;
Fraioli, Francesco;
Guedj, Eric;
Morbelli, Silvia;
Tolboom, Nelleke;
Traub-Weidinger, Tatjana;
Van Weehaeghe, Donatienne;
Barthel, Henryk

Publication type:

Article

알츠하이머병에서 항아밀로이드 단일클론항체 치료제에 의한 아밀로이드 관련 영상 이상: 표준 자기공명영상 프로토콜에 대한 전문가 권고안

Published in:

Journal of the Korean Society of Radiology (2951-0805), 2025, v. 86, n. 1, p. 34, doi. 10.3348/jksr.2024.0147

By:

김지민;
김은희;
박미나;
배윤정;
서종현;
유성혜;
임영희;
이호준;
최진욱;
오세원;
문원진

Publication type:

Article

항-아밀로이드 베타 단일클론 항체 치료에서 발생하는 항-아밀로이드 영상 이상 소견: 영상의학과 의사를 위한 최신 업데이트

Published in:

Journal of the Korean Society of Radiology (2951-0805), 2025, v. 86, n. 1, p. 17, doi. 10.3348/jksr.2024.0140

By:

정소영;
서종현;
임재성;
최양신;
김호성;
김상준;
이재홍

Publication type:

Article

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective.

Published in:

British Journal of Clinical Pharmacology, 2025, v. 91, n. 5, p. 1352, doi. 10.1002/bcp.70021

By:

Bobbins, Amy;
Davies, Miranda;
Lynn, Elizabeth;
Roy, Debabrata;
Yeomans, Alison;
Shakir, Saad A. W.

Publication type:

Article

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13195-024-01441-8

By:

Honig, Lawrence S.;
Sabbagh, Marwan N.;
van Dyck, Christopher H.;
Sperling, Reisa A.;
Hersch, Steven;
Matta, Andre;
Giorgi, Luigi;
Gee, Michelle;
Kanekiyo, Michio;
Li, David;
Purcell, Derk;
Dhadda, Shobha;
Irizarry, Michael;
Kramer, Lynn

Publication type:

Article

The search for clarity regarding "clinically meaningful outcomes" in Alzheimer disease clinical trials: CLARITY-AD and Beyond.

Published in:

Alzheimer's Research & Therapy, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13195-024-01412-z

By:

Tarawneh, Rawan;
Pankratz, Vernon S.

Publication type:

Article

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.

Published in:

Alzheimer's Research & Therapy, 2022, p. 1, doi. 10.1186/s13195-022-01124-2

By:

McDade, Eric;
Cummings, Jeffrey L.;
Dhadda, Shobha;
Swanson, Chad J.;
Reyderman, Larisa;
Kanekiyo, Michio;
Koyama, Akihiko;
Irizarry, Michael;
Kramer, Lynn D.;
Bateman, Randall J.

Publication type:

Article

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01129-x

By:

Dhadda, Shobha;
Kanekiyo, Michio;
Li, David;
Swanson, Chad J.;
Irizarry, Michael;
Berry, Scott;
Kramer, Lynn D.;
Berry, Donald A.

Publication type:

Article

Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real‐word study on aducanumab and lecanemab.

Published in:

European Journal of Neurology, 2025, v. 32, n. 1, p. 1, doi. 10.1111/ene.16534

By:

Logroscino, G.;
Urso, D.;
Gnoni, V.;
Giugno, A.;
Vilella, D.;
Castri, A.;
Barone, R.;
Nigro, S.;
Zecca, C.;
De Blasi, R.;
Introna, A.

Publication type:

Article

Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds.

Published in:

Neuropathology & Applied Neurobiology, 2025, v. 51, n. 3, p. 1, doi. 10.1111/nan.70022

By:

Peralta Reyes, Fernanda S.;
Sommerhage, Simon;
Willbold, Dieter;
Schröder, Gunnar F.;
Gremer, Lothar

Publication type:

Article

Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43933-5

By:

Solopova, Elena;
Romero-Fernandez, Wilber;
Harmsen, Hannah;
Ventura-Antunes, Lissa;
Wang, Emmeline;
Shostak, Alena;
Maldonado, Jose;
Donahue, Manus J.;
Schultz, Daniel;
Coyne, Thomas M.;
Charidimou, Andreas;
Schrag, Matthew

Publication type:

Article

Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease.

Published in:

Annals of Pharmacotherapy, 2024, v. 58, n. 10, p. 1045, doi. 10.1177/10600280231218253

By:

Park, Juliane;
Simpson, Carson;
Patel, Katie

Publication type:

Article

Morbus Alzheimer: Neues bei Therapie und Diagnose.

Published in:

Trillium-Diagnostik, 2024, v. 22, n. 1, p. 5

By:

Gruber, Rudolf

Publication type:

Article

A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease.

Published in:

CNS Drugs, 2024, v. 38, n. 7, p. 493, doi. 10.1007/s40263-024-01097-w

By:

Rosenbloom, Michael H.;
O'Donohue, Tricia;
Zhou-Clark, Domi;
Mala, Deepashni;
Frazier, Andrew;
Tarrant, Michael;
Modrijan, Michelle;
Riveira, Melora;
Chapman, Darla;
Griffin, Yvonne;
Shakalis, Lauren;
Grabowski, Thomas J.

Publication type:

Article

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.

Published in:

CNS Drugs, 2024, v. 38, n. 3, p. 169, doi. 10.1007/s40263-024-01067-2

By:

Qiao, Yue;
Gu, Jian;
Yu, Miao;
Chi, Yuewei;
Ma, Ying

Publication type:

Article

Updates on pharmacological treatment for Alzheimer's disease.

Published in:

Polish Journal of Neurology & Neurosurgery / Neurologia i Neurochirurgia Polska, 2024, v. 58, n. 2, p. 150, doi. 10.5603/pjnns.96286

By:

Tipton, Philip W.

Publication type:

Article